Concurrent or previous other malignancy within  years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in-situ of the cervix, or other noninvasive or indolent malignancy
Other malignancy active within the previous  years except for basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast that has completed curative therapy
Any other prior malignancy from which the patient has been disease free for less than  years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of any site.
History of another cancer is exclusionary unless it is believed to be likely cured or is unlikely to be fatal in the next  years (e.g. squamous cell carcinoma, superficial bladder cancer, chronic lymphocytic leukemia, etc)
Other prior malignancy, except for adequately treated basal or squamous cell skin cancer or superficial bladder cancer, or any other cancer from which the subject has been disease-free for at least  years;
Any other prior malignancy from which the patient has been disease free for less than  years, with the exception of adequately treated and basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of any site
History of other malignancies (except adequately treated Stage  cancer, cured basal cell carcinoma, superficial bladder cancer, Breast ductal carcinoma in situ (DCIS), or carcinoma in situ of the cervix) unless documented free of cancer for ? years.
Any other malignancy form which the patient has been disease-free for less than  years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix
Had a prior malignancy. Adequately treated basal cell or squamous cell carcinoma of skin or superficial bladder cancer that has not spread behind the connective tissue layer (i.e., pTis, pTa, and pT) is allowed, as well as any other cancer for which treatment has been completed  years before randomization and from which the subject has been disease-free
Any other prior malignancy from which the patient has been disease free for less than  years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of any site
Any other malignancy from which the patient has been disease-free for less than  years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix
Any other active malignancy other than the endometrial cancer, that is progressing or requiring active treatment with the exception of basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of any site
Patients are excluded if they have a history of any other malignancy from which the patient has been disease-free for less than  years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix, or stage  or  cutaneous melanoma
History of other malignancies except cured basal cell carcinoma, cutaneous squamous cell carcinoma, melanoma in situ, superficial bladder cancer or carcinoma in situ of the cervix; for other malignancies, must be documented to be free of cancer for >=  years; all other cases can be considered on a case by case basis at the discretion of the principal investigator
Current or previous other malignancy within  years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy without sponsor approval
Current or previous other malignancy within  years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive malignancy.
History of other malignancies except cured basal cell carcinoma, cutaneous squamous cell carcinoma, melanoma in situ, superficial bladder cancer or carcinoma in situ of the cervix unless documented free of cancer for ? years.
Patients have a history of any other malignancy from which the patient has been disease-free for less than  years, with the exception of adequately treated basal or squamous cell carcinoma of skin, superficial bladder cancer or carcinoma in situ of cervix, American Joint Committee on Cancer (AJCC) (version .) stage  or I breast cancer, AJCC (version .) stage I, or II prostate cancer
Active malignancy, other than superficial basal cell and superficial squamous (skin) cell, or carcinoma in situ of the cervix within last  years
If a cancer survivor, the disease free interval is less than  years, with the exception of superficial cutaneous basal cell or squamous cell carcinomas
Any other malignancy from which the patient has been disease-free for less than  years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, or ductal carcinoma in situ (DCIS); patients with prior malignancies that are not considered to be an active problem may be enrolled at the discretion of the principal investigator, regardless of time frame
Any other malignancy from which the patient has been disease-free for less than  years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix, breast, or prostate
Active malignancy (exceptions: adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently remission) less than or equal to (<=)  years prior to enrollment
Prior malignancy active within the previous  years (exceptions include the tumor under investigation in this trial, and locally recurring cancers that have undergone curative treatment, such as resected basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the prostate, cervix or breast)
History of other malignancies (except cured basal cell carcinoma, superficial bladder cancer or carcinoma in situ of the cervix) unless documented free of cancer for >/=  years.
Diagnosis of any other malignancy within  years prior to enrollment. However, adequately treated basal cell or squamous cell skin cancer or non-invasive superficial bladder cancer or carcinoma in situ of the bladder, breast or cervix; or prostate cancer of low grade (Gleason ?) or surveillance without any plans for treatment intervention (e.g., surgery, radiation, or castration) are allowed;
RENAL & BLADDER: Other prior malignancy (exceptions: adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently in complete remission) ?  years prior to enrollment
Any other malignancy from which the patient has been disease-free for less than  years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix.
Patients are excluded if they have a history of any other malignancy from which the patient has been disease-free for less than  years, with the exception of adequately treated (surgery or radiation) and cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, or localized adenocarcinoma of the cervix
EXCLUSION FOR ENROLLMENT: Any other malignancy from which the patient has been disease-free for less than  years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, and carcinoma in situ of the cervix
Any other prior malignancy from which the patient has been disease free for less than  years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of any site or any other cancer
Any other prior malignancy from which the patient has been disease free for less than  years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of any site or any other cancer
Any other malignancy from which the patient has been disease-free for less than  years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix
Patient with prior malignancies other than ovarian cancer for which the patient has not been disease free for  years or more, except treated and cured basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix
Patients are ineligible if they have a history of any other malignancy from which the patient has been disease-free for less than  years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix
Other prior malignancy less than or equal to  years prior to randomization with the exception of squamous or basal cell skin carcinoma or non-invasive superficial bladder cancer
Patients are excluded if they have a history of any other malignancy from which the patient has been disease-free for less than  years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix
Exclusion criteria for leukapheresis: Any other malignancy from which the patient has been disease-free for less than  years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or melanoma in-situ.
Patients are excluded if they have a history of any other malignancy from which the patient has been disease-free for less than  years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix
Any other malignancy from which the patient has been disease-free for less than  years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix
Any other malignancy from which the patient has been disease-free for less than  years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix
COHORT A: Any other malignancy from which the patient has been disease-free for less than  years, with the exception of adequately treated and cured basal cell or squamous cell skin cancer or superficial bladder cancer
COHORT B: Any other malignancy from which the patient has been disease-free for less than  years, with the exception of adequately treated and cured basal cell or squamous cell skin cancer or superficial bladder cancer
History or evidence of any of the following conditions: any prior malignancy (other than adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently in complete remission) within  years prior to randomization; severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events, or clinically significant ventricular arrhythmias within  months prior to randomization; uncontrolled hypertension; gastrointestinal disorder affecting absorption; active infection; and, any other condition that, in the opinion of the investigator, would impair the patient's ability to comply with study procedures
History of other active malignancy, other than superficial basal cell and superficial squamous cell, or carcinoma in situ of the cervix within last  years.
Any other malignancy from which the patient has been disease-free for less than  years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix
Any other active malignancy with the exception of adequately treated basal or squamous cell skin cancer or superficial bladder cancer
Active second malignancy, other than superficial basal cell and superficial squamous (skin) cell, or carcinoma in situ of the cervix within last five years
Any other malignancy from which the patient has been disease-free for less than  years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix
Subjects with melanoma who have another active, concurrent, malignant disease are not eligible, with the exception of subjects with adequately treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, or other cancers that are in remission/not measurable
Patient has another primary tumor, with the exception of conventional basal cell carcinoma, superficial bladder cancer, melanoma in situ, or treated prostate cancer currently without biochemical or radiographic evidence of active disease
Current or previous other malignancy within  years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive malignancy.
Current or previous other malignancy within  years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy without sponsor approval.
Any other malignancy (except for simultaneous HNSCC primaries, appropriately treated superficial basal cell skin cancer and surgically cured cervical cancer in situ) unless free of disease for at least five years
History of prior malignancy within the past  years with the exception of curatively treated basal cell or squamous cell carcinoma of the skin or superficial bladder or other stage I or II cancer in complete remission for at least  months
Any other malignancy from which the patient has been disease-free for less than  years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix
Prior malignancy. Adequately treated basal cell or squamous cell skin or superficial (pTis, pTa, and pT) bladder cancer are allowed, as well as any other cancer for which treatment has been completed ? years ago and from which the patient has been disease-free for ? years.
No other malignancy is allowed except for the following: adequately treated basal or squamous cell carcinoma, superficial bladder cancer, any carcinoma in situ or any other cancer from which the patient has been disease free for at least  years
Previously or current malignancies at other sites within the last  years, with the exception of adequately treated in situ carcinoma of the cervix, basal or squamous cell carcinoma of the skin, prostate cancer that does not require active treatment per National Comprehensive Cancer Network (NCCN) guidelines, superficial bladder cancer or other noninvasive indolent or stage  malignancy without sponsor approval
History of other malignancies except cured basal cell carcinoma, cutaneous squamous cell carcinoma, melanoma in situ, superficial bladder cancer or carcinoma in situ of the cervix unless documented free of cancer for ? years.
Concurrent active malignancy other than adequately treated nonmelanomatous cell skin cancers, superficial bladder cancer, or carcinoma in situ of the cervix or breast;
History of other malignancies (except cured basal cell carcinoma, superficial bladder cancer or carcinoma in situ of the cervix) unless documented free of cancer for  or more years.
Patients are excluded if they have a history of any other malignancy from which the patient has been disease-free for less than  years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix
Prior malignancy other than adequately treated basal or squamous cell carcinoma of the skin, superficial bladder cancer, low-grade cervical cancer, non-metastatic prostate cancer, or have been disease-free for at least  years
Any other malignancy form which the patient has been disease-free for less than  years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, or ductal carcinoma in situ (DCIS); patients with prior malignancies that are not considered to be an active problem may be enrolled at the discretion of the investigator, regardless of time frame
Active second malignancy, other than superficial basal cell and superficial squamous (skin) cell, or carcinoma in situ of the cervix within last five years
Prior history of any other malignancy within the last  years, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer
No other malignancy within the past  years (skin basal cell or cutaneous superficial squamous cell carcinoma or superficial bladder cancer are exempt from this criterion)
Patient undergoing active treatment for non-prostate malignancy, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer
SUB-STUDY I: Prior history of any other malignancy within the last  years, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer
SUB-STUDY II: Prior history of any other malignancy within the last  years, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer
SUB-STUDY III: Prior history of any other malignancy within the last  years, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer
Patient undergoing active treatment for non-prostate malignancy, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer
Prior history of any other malignancy within last  years, other than skin basal cell carcinoma or superficial bladder cancer
Prior history of any other malignancy within the last  years, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer
Prior history of any other malignancy within the last  years, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer
Other malignancy active within the previous  years except for basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast that has completed curative therapy.